Skip to content
Screener

Regenxbio RGNX Q4 2025 Annual earnings

Reported March 5, 2026 · Before market open

Revenue$30.3MMiss by $13.6M
EPS-$1.30Miss by $0.29
Revenue estimate$44.0M
EPS estimate-$1.01

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$15.9M
EPS estimate-$1.21

Financials

Q4 2025

Income statement

See full
Revenue$30.3M+43.0%
Operating income-$57.6M-12.2%
Net income-$67.1M-31.2%
EPS (diluted)-$1.30-30.0%

Balance sheet

See full
Cash & equivalents$34.5M-40.1%
Total debt$73.5M-10.4%
Total equity$102.7M-60.4%
Total assets$453.0M-2.8%

Cash flow

See full
Operating cash flow-$52.3M-65.3%
CapEx$508.0K-52.9%
Free cash flow-$52.8M-61.4%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$728.97M+90.3%
Enterprise value$768.01M+88.5%
P/S4.3×-0.3×

Profitability

See full
Operating margin-94.6%-37.7pp
Net margin-113.8%-41.9pp
FCF margin-74.1%-29.2pp

Returns & leverage

See full
Return on equity-107%+56.6pp
Debt / equity0.7×+0.4×
Current ratio2.4×-0.3×

Segments

By product

See full
Other Service Revenue$1.8M+321%
Nippon Shinyaku Services$1.4M—

FAQ

When did Regenxbio report Q4 2025 earnings?
Regenxbio (RGNX) reported Q4 2025 earnings on March 5, 2026 before market open.
What were Regenxbio's Q4 2025 revenue and EPS?
Regenxbio reported revenue of $30.3M and eps of $-1.30 for Q4 2025.
Did Regenxbio beat estimates in Q4 2025?
Revenue missed the consensus estimate of $44.0M by $13.6M. EPS missed the consensus estimate of $-1.01 by $0.29.
How did Regenxbio's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 43.0% from $21.2M a year earlier and eps declined 28.7% from $-1.01.
Where can I find Regenxbio's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-092566) and the 10-K periodic report (0001193125-26-094013) directly on SEC EDGAR. The filing index links above go to sec.gov.